New radiation drug targets brain tumors in kids

NCT ID NCT05610891

Ongoing Disease control Sponsor: Cellectar Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called CLR 131, a targeted radiotherapy, in children, adolescents, and young adults (ages 10 to 25) with high-grade glioma that has returned or not responded to treatment. The goal is to find the best dose and see if it is safe and can shrink tumors or slow the disease. About 50 participants will receive the drug intravenously, and their progress will be tracked with MRI scans and safety checks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CLR 131 (iopofosine I 131), a targeted radiotherapy drug given intravenously
What this could lead to: If it works, this could provide a new treatment option for young patients with high-grade glioma that has come back or not responded to standard therapy.
What could go wrong: This is an early phase 1b trial with only 50 participants, so the results may not confirm effectiveness. The drug also carries risks like radiation-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE GLIOMA

Contacts and locations

Locations

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Stanford University

Palo Alto, California, 94304, United States
Texas Children's Cancer Center, Baylor College of Medicine

Houston, Texas, 77030, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of Wisconsin, Carbone Cancer Center

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.